Back to News
Market Impact: 0.2
Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan
Source: PR Newswire
Healthcare & BiotechM&A & Restructuring
Minghui Pharmaceutical and ASKA Pharmaceutical entered into an exclusive license agreement for development and commercialization of MHB018A in Japan. The announcement provides no financial terms, development timeline, or expected commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Host Hotels & Resorts CEO on 3Q Quarterly Results
- NextDC shares surge 43% as Goodman, Digital Realty buy stake
- Australia’s 188-year-old retailer David Jones enters administration, faces sale